Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Alpha Teknova Inc (TKNO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: TKNO (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -1.3% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 277.34M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 534264 | Beta 0.42 | 52 Weeks Range 1.16 - 10.37 | Updated Date 04/2/2025 |
52 Weeks Range 1.16 - 10.37 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.57 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-05 | When - | Estimate -0.12 | Actual -0.11 |
Profitability
Profit Margin -70.86% | Operating Margin (TTM) -59.67% |
Management Effectiveness
Return on Assets (TTM) -12.51% | Return on Equity (TTM) -31.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 277113023 | Price to Sales(TTM) 7.35 |
Enterprise Value 277113023 | Price to Sales(TTM) 7.35 | ||
Enterprise Value to Revenue 7.34 | Enterprise Value to EBITDA -6.23 | Shares Outstanding 53436800 | Shares Floating 8666916 |
Shares Outstanding 53436800 | Shares Floating 8666916 | ||
Percent Insiders 9.21 | Percent Institutions 82.67 |
Analyst Ratings
Rating 4.2 | Target Price 8 | Buy - | Strong Buy 3 |
Buy - | Strong Buy 3 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Alpha Teknova Inc
Company Overview
History and Background
Alpha Teknova Inc. was founded in 1975. Initially focused on custom media formulations, it expanded into manufacturing a broader range of life science reagents and solutions. The company went public in 2021.
Core Business Areas
- Cell Culture: Supplies cell culture media, sera, and supplements for research and biomanufacturing applications.
- Genomics: Offers reagents and kits for nucleic acid purification, amplification, and sequencing.
- Proteomics: Provides reagents for protein purification, detection, and analysis.
- Molecular Biology: Manufactures reagents for cloning, PCR, and other molecular biology techniques.
- Custom Solutions: Offers custom solutions including custom formulation, filling, packaging and kitting.
Leadership and Structure
Todd Nelson serves as the CEO. The company has a typical corporate structure with departments for research and development, manufacturing, sales, and marketing, all reporting to a board of directors.
Top Products and Market Share
Key Offerings
- Cell Culture Media: A range of cell culture media formulations for various cell types. Market share data is difficult to pinpoint, but they are competing with larger players like Thermo Fisher Scientific and Cytiva. Revenue contribution to total is about 40%.
- Competitors: Thermo Fisher Scientific (TMO), Cytiva (part of Danaher DHR), Corning (GLW)
- Competitors: New England Biolabs (Private), QIAGEN (QGEN), Bio-Rad Laboratories (BIO)
- Molecular Biology Reagents: Enzymes, buffers, and kits for DNA and RNA manipulation. Market share data is difficult to pinpoint, and they compete with New England Biolabs (privately held) and QIAGEN. Revenue contribution to total is about 25%.
- Competitors: Thermo Fisher Scientific (TMO), Avantor (AVTR)
- Custom Solutions: Alpha Teknova offers contract development and manufacturing services to other pharmaceutical companies. This accounts for about 35% of their business.
Market Dynamics
Industry Overview
The life science reagents market is growing, driven by increasing research funding, advancements in biotechnology, and the growth of the biopharmaceutical industry.
Positioning
Alpha Teknova is a niche player, focusing on providing high-quality reagents and custom solutions. Their competitive advantages include responsiveness and flexibility. They are focused on the market for GMP reagents and biologics.
Total Addressable Market (TAM)
The total addressable market is estimated to be several billion dollars annually. Alpha Teknova aims to capture a larger share through innovation and expansion of its product portfolio. The cell culture market is expected to grow to US$8.8 billion in 2028. Alpha Teknova's TAM represents a small fraction of that amount.
Upturn SWOT Analysis
Strengths
- High-quality products
- Custom solution capabilities
- Strong customer relationships
- GMP-grade capabilities
Weaknesses
- Smaller scale compared to major competitors
- Limited brand recognition
- Dependence on a few key products
Opportunities
- Expanding into new product areas
- Acquiring smaller companies
- Increasing sales in emerging markets
- Capitalizing on the growth in cell and gene therapy
- Partnerships with larger biopharmaceutical companies.
Threats
- Competition from larger companies with greater resources
- Price pressures
- Changes in regulatory requirements
- Economic downturns affecting research funding
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- TMO
- DHR
- QGEN
Competitive Landscape
Alpha Teknova faces intense competition from larger, more established companies. Its strength lies in custom solutions and responsiveness, but it needs to scale to compete effectively.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Alpha Teknova has experienced growth in recent years, driven by increasing demand for its products and services.
Future Projections: Analysts project continued growth for Alpha Teknova, driven by the expanding life science reagents market.
Recent Initiatives: Recent initiatives include expanding manufacturing capacity and developing new products.
Summary
Alpha Teknova is a niche player in the life science reagents market with strengths in custom solutions and GMP capabilities. It faces competition from larger companies and needs to scale and expand its product portfolio to maintain growth. The company's ability to capitalize on opportunities in cell and gene therapy and custom solutions will be crucial for its future success. They should also work on brand recognition.
Similar Companies
AVTR
Avantor Inc
AVTR
Avantor Inc
BIO
Bio-Rad Laboratories Inc
BIO
Bio-Rad Laboratories Inc
DHR
Danaher Corporation
DHR
Danaher Corporation
TMO
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (if available)
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data is based on available information and may not be fully accurate. Market share data is estimated and may vary. Please consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alpha Teknova Inc
Exchange NASDAQ | Headquaters Hollister, CA, United States | ||
IPO Launch date 2021-06-25 | President, CEO & Director Mr. Stephen Gunstream | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 173 | Website https://www.teknova.com |
Full time employees 173 | Website https://www.teknova.com | ||
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.